Dr. P.J. Klasse, MD, PhD - Weill Cornell Medicine, Cornell University - Professor

Dr. P.J. Klasse

MD, PhD

Weill Cornell Medicine, Cornell University

Professor

New York, NY | United States

Main Specialties: Other

Additional Specialties: Virology

Dr. P.J. Klasse, MD, PhD - Weill Cornell Medicine, Cornell University - Professor

Dr. P.J. Klasse

MD, PhD
Introduction

Primary Affiliation: Weill Cornell Medicine, Cornell University - New York, NY , United States

Specialties:

Additional Specialties:

Research Interests:

Metrics

77

Publications

240

Profile Views

905

Reads

3589

PubMed Central Citations

Education
Oct 1996
MRC research Fellow
LMCB, University College London
Jan 1993
EMBO Fellow
Institute of Cancer Research, London
Dec 1992
PhD
Lund Univesrity
Jun 1986
MD
Lund University
Experience
Jul 2003
Professor
Scientist
Oct 2000
Lecturer
Scientist
Top co-authors
John P Moore
John P Moore

Weill Medical College of Cornell University

66
Rogier W Sanders
Rogier W Sanders

Academic Medical Center

36
Andrew B Ward
Andrew B Ward

The Scripps Research Institute

20
Thomas J Ketas
Thomas J Ketas

Weill Medical College of Cornell University

19
Ian A Wilson
Ian A Wilson

The Scripps Research Institute

18
Albert Cupo
Albert Cupo

Weill Medical College of Cornell University

14
Anila Yasmeen
Anila Yasmeen

Weill Medical College of Cornell University

14
Ronald S Veazey
Ronald S Veazey

Tulane National Primate Research Center

13
Dennis R Burton
Dennis R Burton

The Scripps Research Institute

13

Publications

77Publications

905Reads

3589PubMed Central Citations

cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate.

Biotechnol Bioeng 2018 Apr 11;115(4):885-899. Epub 2017 Dec 11.

Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York.

View Article
April 2018
15 Reads
9 PubMed Central Citations(source)
4.13 Impact Factor

Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization.

Cell Rep 2017 Aug;20(8):1805-1817

Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam 1105 AZ, the Netherlands; Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10021, USA. Electronic address:

View Article
August 2017
19 Reads
14 PubMed Central Citations(source)
7.21 Impact Factor

Recognition of HIV-inactivating peptide triazoles by the recombinant soluble Env trimer, BG505 SOSIP.664.

Proteins 2017 05 11;85(5):843-851. Epub 2017 Mar 11.

Department of Biochemistry and Molecular Biology, Drexel University, Philadelphia, Pennsylvania, 19102.

View Article
May 2017
7 Reads
1 PubMed Central Citation(source)
2.63 Impact Factor

A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic β-Hairpin Structure.

Immunity 2017 04;46(4):690-702

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, International AIDS Vaccine Initiative Neutralizing Antibody Center and Collaboration for AIDS Vaccine Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA. Electronic address:

View Article
April 2017
16 Reads
23 PubMed Central Citations(source)
21.56 Impact Factor

HIV-1 Escape from a Peptidic Anchor Inhibitor through Stabilization of the Envelope Glycoprotein Spike.

J Virol 2016 Dec 14;90(23):10587-10599. Epub 2016 Nov 14.

Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands

View Article
December 2016
13 Reads
5 PubMed Central Citations(source)
4.44 Impact Factor

Quantitative Correlation between Infectivity and Gp120 Density on HIV-1 Virions Revealed by Optical Trapping Virometry.

J Biol Chem 2016 Jun 25;291(25):13088-97. Epub 2016 Apr 25.

From the Department of Pharmaceutical Sciences, College of Pharmacy, and Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, Michigan 48109 and

View Article
June 2016
11 Reads
7 PubMed Central Citations(source)
4.57 Impact Factor

Binding of inferred germline precursors of broadly neutralizing HIV-1 antibodies to native-like envelope trimers.

Virology 2015 Dec 1;486:116-20. Epub 2015 Oct 1.

Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands; Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10065, USA. Electronic address:

View Article
December 2015
7 Reads
12 PubMed Central Citations(source)
3.32 Impact Factor

Short Communication: Virion Aggregation by Neutralizing and Nonneutralizing Antibodies to the HIV-1 Envelope Glycoprotein.

AIDS Res Hum Retroviruses 2015 Nov 20;31(11):1160-5. Epub 2015 Jul 20.

1 Department of Microbiology and Immunology, Weill Cornell Medical College , Cornell University, New York, New York.

View Article
November 2015
10 Reads
3 PubMed Central Citations(source)
2.33 Impact Factor

Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.

J Virol 2015 Oct 5;89(20):10383-98. Epub 2015 Aug 5.

Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA Center for HIV-1/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID), La Jolla, California, USA

View Article
October 2015
16 Reads
33 PubMed Central Citations(source)
4.44 Impact Factor

Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike.

Nat Commun 2015 Sep 25;6:8167. Epub 2015 Sep 25.

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California 92037, USA.

View Article
September 2015
8 Reads
25 PubMed Central Citations(source)
10.74 Impact Factor

Predicting first traversal times for virions and nanoparticles in mucus with slowed diffusion.

Biophys J 2015 Jul;109(1):164-72

School of Mathematics and Statistics, UNSW Australia, Sydney, New South Wales, Australia. Electronic address:

View Article
July 2015
8 Reads
2 PubMed Central Citations(source)
3.97 Impact Factor

What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?

J Virol 2015 Jun 25;89(11):5981-95. Epub 2015 Mar 25.

Department of Microbiology and Immunology, Weill Cornell Medical College, Cornell University, New York, New York, USA

View Article
June 2015
6 Reads
7 PubMed Central Citations(source)
4.44 Impact Factor

Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer.

PLoS Pathog 2015 Mar 25;11(3):e1004767. Epub 2015 Mar 25.

Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, United States of America.

View Article
March 2015
7 Reads
48 PubMed Central Citations(source)

Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits.

Retrovirology 2014 May 29;11:41. Epub 2014 May 29.

Department of Microbiology and Immunology, Weill Cornell Medical College, Cornell University, New York, USA.

View Article
May 2014
26 Reads
72 PubMed Central Citations(source)
4.18 Impact Factor

Stable 293 T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies.

Retrovirology 2014 Apr 25;11:33. Epub 2014 Apr 25.

Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY, USA.

View Article
April 2014
11 Reads
26 PubMed Central Citations(source)
4.18 Impact Factor

Targeting B-cell germlines and focusing affinity maturation: the next hurdles in HIV-1-vaccine development?

Expert Rev Vaccines 2014 Apr;13(4):449-52

View Article
April 2014
8 Reads
8 PubMed Central Citations(source)
4.21 Impact Factor

Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer.

Science 2013 Dec 31;342(6165):1484-90. Epub 2013 Oct 31.

National Resource for Automated Molecular Microscopy, The Scripps Research Institute, La Jolla, CA 92037, USA.

View Article
December 2013
21 Reads
316 PubMed Central Citations(source)
31.48 Impact Factor

Clinical adjuvant combinations stimulate potent B-cell responses in vitro by activating dermal dendritic cells.

PLoS One 2013 20;8(5):e63785. Epub 2013 May 20.

Department of Microbiology and Immunology, Weill Cornell Medical College, New York, New York, USA.

View Article
December 2013
10 Reads
3 PubMed Central Citations(source)
3.23 Impact Factor

Crystal structure of a soluble cleaved HIV-1 envelope trimer.

Science 2013 Dec 31;342(6165):1477-83. Epub 2013 Oct 31.

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.

View Article
December 2013
10 Reads
407 PubMed Central Citations(source)
31.48 Impact Factor

Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation.

Proc Natl Acad Sci U S A 2013 Nov 21;110(45):18256-61. Epub 2013 Oct 21.

Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY 10065.

View Article
November 2013
11 Reads
93 PubMed Central Citations(source)
9.81 Impact Factor

Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein.

J Virol 2013 Sep 3;87(17):9873-85. Epub 2013 Jul 3.

Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.

View Article
September 2013
8 Reads
45 PubMed Central Citations(source)
4.44 Impact Factor

Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers.

J Virol 2013 Sep 3;87(17):9865-72. Epub 2013 Jul 3.

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA.

View Article
September 2013
8 Reads
45 PubMed Central Citations(source)
4.44 Impact Factor

Use of G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants.

J Virol 2013 Jun 6;87(12):6569-81. Epub 2013 Mar 6.

Department of Microbiology and Immunology, Weill Cornell Medical College, New York, New York, USA.

View Article
June 2013
10 Reads
8 PubMed Central Citations(source)
4.44 Impact Factor

Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5.

J Virol 2013 Mar 26;87(5):2401-11. Epub 2012 Dec 26.

Department of Microbiology, Perelman School of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.

View Article
March 2013
23 Reads
36 PubMed Central Citations(source)
4.44 Impact Factor

Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9.

Proc Natl Acad Sci U S A 2013 Mar 20;110(11):4351-6. Epub 2013 Feb 20.

Department of Integrative Structural and Computational Biology, International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.

View Article
March 2013
8 Reads
146 PubMed Central Citations(source)
9.81 Impact Factor

Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques.

J Antimicrob Chemother 2013 Mar 30;68(3):678-83. Epub 2012 Oct 30.

School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.

View Article
March 2013
10 Reads
27 PubMed Central Citations(source)
5.31 Impact Factor

Partial protection against multiple RT-SHIV162P3 vaginal challenge of rhesus macaques by a silicone elastomer vaginal ring releasing the NNRTI MC1220.

J Antimicrob Chemother 2013 Feb 28;68(2):394-403. Epub 2012 Oct 28.

School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.

View Article
February 2013
12 Reads
11 PubMed Central Citations(source)
5.31 Impact Factor

HIV-1 gp120 impairs the induction of B cell responses by TLR9-activated plasmacytoid dendritic cells.

J Immunol 2012 Dec 24;189(11):5257-65. Epub 2012 Oct 24.

Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY 10021, USA.

View Article
December 2012
4 Reads
9 PubMed Central Citations(source)
4.92 Impact Factor

Potent induction of antibody-secreting B cells by human dermal-derived CD14+ dendritic cells triggered by dual TLR ligation.

J Immunol 2012 Dec 16;189(12):5729-44. Epub 2012 Nov 16.

Department of Microbiology and Immunology, Weill Cornell Medical College, Cornell University, New York, NY 10021, USA.

View Article
December 2012
10 Reads
10 PubMed Central Citations(source)
4.92 Impact Factor

Good CoP, bad CoP? Interrogating the immune responses to primate lentiviral vaccines.

Retrovirology 2012 Oct 1;9:80. Epub 2012 Oct 1.

Department of Microbiology and Immunology, Weill Cornell Medical College, Cornel University, 1300 York Avenue, Box 62, New York, NY 10065-4896, USA.

View Article
October 2012
6 Reads
6 PubMed Central Citations(source)
4.18 Impact Factor

The molecular basis of HIV entry.

Authors:
Per Johan Klasse

Cell Microbiol 2012 Aug 5;14(8):1183-92. Epub 2012 Jun 5.

Department of Microbiology and Immunology, Cornell University, Weill Cornell Medical College, 1300 York Avenue, Box 62, New York, NY 10065-4896, USA.

View Article
August 2012
7 Reads
42 PubMed Central Citations(source)
4.92 Impact Factor

Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance.

Virology 2012 Jul 19;428(2):86-97. Epub 2012 Apr 19.

Department of Microbiology and Immunology, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10065, USA.

View Article
July 2012
10 Reads
8 PubMed Central Citations(source)
3.32 Impact Factor

V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc.

Virology 2012 Jun 16;427(2):158-65. Epub 2012 Mar 16.

Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10065, USA.

View Article
June 2012
5 Reads
17 PubMed Central Citations(source)
3.32 Impact Factor

Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission.

Proc Natl Acad Sci U S A 2012 May 14;109(22):8694-8. Epub 2012 May 14.

Beth Israel Deaconess Medical Center, Boston, MA 02115, USA.

View Article
May 2012
9 Reads
17 PubMed Central Citations(source)
9.81 Impact Factor

Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques.

Antimicrob Agents Chemother 2012 May 13;56(5):2251-8. Epub 2012 Feb 13.

School of Pharmacy, Queen’s University Belfast, Belfast, United Kingdom.

View Article
May 2012
8 Reads
27 PubMed Central Citations(source)
4.48 Impact Factor

Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses.

J Virol 2012 Mar 28;86(5):2488-500. Epub 2011 Dec 28.

Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), University of Amsterdam, The Netherlands.

View Article
March 2012
5 Reads
28 PubMed Central Citations(source)
4.44 Impact Factor

Occluding the mannose moieties on human immunodeficiency virus type 1 gp120 with griffithsin improves the antibody responses to both proteins in mice.

AIDS Res Hum Retroviruses 2012 Feb 27;28(2):206-14. Epub 2011 Jul 27.

Department of Microbiology and Immunology, Weill Cornell Medical College, New York, New York 10021, USA.

View Article
February 2012
9 Reads
15 PubMed Central Citations(source)
2.33 Impact Factor

Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors.

Virology 2012 Jan 22;422(1):22-36. Epub 2011 Oct 22.

Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10065-4896, USA.

View Article
January 2012
9 Reads
15 PubMed Central Citations(source)
3.32 Impact Factor

How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?

AIDS Res Hum Retroviruses 2012 Jan 20;28(1):1-15. Epub 2011 May 20.

Department of Microbiology and Immunology, Cornell University, Weill Cornell Medical College, New York, New York 10065-4896, USA.

View Article
January 2012
14 Reads
37 PubMed Central Citations(source)
2.33 Impact Factor

Animal models for microbicide studies.

Curr HIV Res 2012 Jan;10(1):79-87

Division of Comparative Pathology, Tulane National Primate Research Center, Tulane University School of Medicine, Covington, LA 70433, USA.

View Article
January 2012
7 Reads
28 PubMed Central Citations(source)
2.13 Impact Factor

Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc.

J Control Release 2011 Dec 12;156(2):161-9. Epub 2011 Aug 12.

School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.

View Article
December 2011
9 Reads
18 PubMed Central Citations(source)
7.70 Impact Factor

Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors.

J Virol 2011 Aug 15;85(16):8227-40. Epub 2011 Jun 15.

Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.

View Article
August 2011
14 Reads
23 PubMed Central Citations(source)
4.44 Impact Factor

Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures.

Proc Natl Acad Sci U S A 2011 Jul 27;108(28):11440-5. Epub 2011 Jun 27.

Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

View Article
July 2011
23 Reads
96 PubMed Central Citations(source)
9.81 Impact Factor

Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.

Proc Natl Acad Sci U S A 2011 Jul 20;108(27):11181-6. Epub 2011 Jun 20.

Department of Immunology and Microbial Science and International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.

View Article
July 2011
26 Reads
123 PubMed Central Citations(source)
9.81 Impact Factor

Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41.

Virology 2011 Apr 26;413(1):47-59. Epub 2011 Feb 26.

Department of Microbiology and Immunology, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10065, USA.

View Article
April 2011
13 Reads
14 PubMed Central Citations(source)
3.32 Impact Factor

Structural and biological mimicry of protein surface recognition by alpha/beta-peptide foldamers.

Proc Natl Acad Sci U S A 2009 Sep 17;106(35):14751-6. Epub 2009 Aug 17.

Department of Chemistry, University of Wisconsin, 1101 University Avenue, Madison, WI 53706, USA.

View Article
September 2009
8 Reads
76 PubMed Central Citations(source)
9.81 Impact Factor

Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo.

Virology 2009 Jun 2;389(1-2):108-21. Epub 2009 May 2.

Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY 10065, USA.

View Article
June 2009
9 Reads
27 PubMed Central Citations(source)
3.32 Impact Factor

Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities.

Virology 2009 May 20;387(2):296-302. Epub 2009 Mar 20.

Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY, USA.

View Article
May 2009
10 Reads
23 PubMed Central Citations(source)
3.32 Impact Factor

Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41.

Proc Natl Acad Sci U S A 2009 Mar 16;106(13):5318-23. Epub 2009 Mar 16.

Department of Microbiology and Immunology, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA.

View Article
March 2009
9 Reads
54 PubMed Central Citations(source)
9.81 Impact Factor

Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249.

Proc Natl Acad Sci U S A 2008 Jul 22;105(30):10531-6. Epub 2008 Jul 22.

Tulane National Primate Research Center, Tulane University Health Sciences Center, Covington, LA 70433, USA.

View Article
July 2008
10 Reads
19 PubMed Central Citations(source)
9.81 Impact Factor

Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission.

Annu Rev Med 2008 ;59:455-71

Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York 10021, USA.

View Article
May 2008
7 Reads
1 PubMed Central Citation(source)
12.93 Impact Factor

Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody.

Authors:
Per Johan Klasse

Virology 2007 Dec 7;369(2):245-62. Epub 2007 Sep 7.

Department of Microbiology and Immunology, Cornell University, Weill Medical College, 1300 York Avenue, Box 62, New York, NY 10021, USA.

View Article
December 2007
11 Reads
44 PubMed Central Citations(source)
3.32 Impact Factor

HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells.

PLoS Pathog 2007 Nov;3(11):e169

Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, United States of America.

View Article
November 2007
11 Reads
77 PubMed Central Citations(source)

HIV-1 pathogenesis: the complexities of the CCR5-CCL3L1 complex.

Cell Host Microbe 2007 Nov;2(5):281-3

Department of Microbiology and Immunology, Weill Medical College of Cornell University, 1300 York Avenue, Box 62, New York, NY 10065-4896, USA.

View Article
November 2007
6 Reads
5 PubMed Central Citations(source)
12.33 Impact Factor

Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes.

Virology 2007 Aug 10;364(2):431-40. Epub 2007 Apr 10.

Dept of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10021, USA.

View Article
August 2007
10 Reads
14 PubMed Central Citations(source)
3.32 Impact Factor

Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands.

Virology 2007 Aug 10;364(2):281-90. Epub 2007 Apr 10.

Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10021, USA.

View Article
August 2007
8 Reads
1 PubMed Central Citation(source)
3.32 Impact Factor

A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.

Virology 2007 Apr 28;360(2):329-40. Epub 2006 Nov 28.

Department of Microbiology and Immunology, Weill Medical College of Cornell University, 1300 York Avenue, Room W-805, New York, NY 10021, USA.

View Article
April 2007
11 Reads
65 PubMed Central Citations(source)
3.32 Impact Factor

Antibodies to West Nile virus: a double-edged sword.

Cell Host Microbe 2007 Apr;1(2):87-9

Department of Microbiology and Immunology, Cornell University, Weill Medical College, 1300 York Avenue, Box 62, New York, NY 10021, USA.

View Article
April 2007
6 Reads
8 PubMed Central Citations(source)
12.33 Impact Factor

Which topical microbicides for blocking HIV-1 transmission will work in the real world?

PLoS Med 2006 Sep;3(9):e351

Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, United States of America.

View Article
September 2006
8 Reads
26 PubMed Central Citations(source)

Dominant-negative effect of hetero-oligomerization on the function of the human immunodeficiency virus type 1 envelope glycoprotein complex.

Virology 2006 Jul 17;351(1):121-32. Epub 2006 Apr 17.

Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10021, USA.

View Article
July 2006
11 Reads
13 PubMed Central Citations(source)
3.32 Impact Factor

How do viral and host factors modulate the sexual transmission of HIV? Can transmission be blocked?

PLoS Med 2006 Feb 28;3(2):e79. Epub 2006 Feb 28.

International AIDS Vaccine Initiative, New York, New York, USA.

View Article
February 2006
11 Reads
17 PubMed Central Citations(source)

Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor.

Nat Med 2005 Dec 6;11(12):1293-4. Epub 2005 Nov 6.

Tulane National Primate Research Center, 18703 Three Rivers Road, Covington, Louisiana 70433, USA.

View Article
December 2005
10 Reads
41 PubMed Central Citations(source)
27.36 Impact Factor

Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion.

Nature 2005 Nov 30;438(7064):99-102. Epub 2005 Oct 30.

Tulane National Primate Research Center, Covington, Louisiana 70433, USA.

View Article
November 2005
41 Reads
120 PubMed Central Citations(source)
42.35 Impact Factor

The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles.

Virology 2005 Jul;338(1):154-72

Department of Microbiology and Immunology, Weill Medical College of Cornell University, 1300 York Avenue, Room W-805, New York, NY 10021, USA.

View Article
July 2005
20 Reads
42 PubMed Central Citations(source)
3.32 Impact Factor

V3: HIV's switch-hitter.

AIDS Res Hum Retroviruses 2005 Feb;21(2):171-89

Department of Structural Biology and Bioinformatics, Centre Medical Universitaire, Geneva, Switzerland.

View Article
February 2005
7 Reads
121 PubMed Central Citations(source)
2.33 Impact Factor

Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses.

Virology 2004 Oct;328(1):19-29

Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.

View Article
October 2004
13 Reads
16 PubMed Central Citations(source)
3.32 Impact Factor

Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types.

AIDS Res Hum Retroviruses 2003 Mar;19(3):177-86

Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York 10021, USA.

View Article
March 2003
7 Reads
18 PubMed Central Citations(source)
2.33 Impact Factor

Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120.

Nat Med 2003 Mar 10;9(3):343-6. Epub 2003 Feb 10.

Tulane National Primate Research Center, Tulane University Health Sciences Center, Covington, Louisiana, USA.

View Article
March 2003
10 Reads
201 PubMed Central Citations(source)
27.36 Impact Factor
Top co-authors
John P Moore
John P Moore

Weill Medical College of Cornell University

66
Rogier W Sanders
Rogier W Sanders

Academic Medical Center

36
Andrew B Ward
Andrew B Ward

The Scripps Research Institute

20
Thomas J Ketas
Thomas J Ketas

Weill Medical College of Cornell University

19
Ian A Wilson
Ian A Wilson

The Scripps Research Institute

18
Albert Cupo
Albert Cupo

Weill Medical College of Cornell University

14
Anila Yasmeen
Anila Yasmeen

Weill Medical College of Cornell University

14
Ronald S Veazey
Ronald S Veazey

Tulane National Primate Research Center

13
Dennis R Burton
Dennis R Burton

The Scripps Research Institute

13